[Current tumor pathology.  Clinical expectations of pathological diagnosis].
Modern histochemical, immunological, genetic and molecular biological techniques now make precise tumour diagnosis and identification of biological subgroups possible. By detecting molecular and genetic aberrations, subgroups with varying clinical courses can be distinguished and treated in a targeted manner with the use of antibodies or tyrosine kinase inhibitors. This development will lead to even more accurate diagnosis and affect therapeutic decisions.
Hiddemann
W
W
Medizinische Klinik III, Klinikum der Universität München, Campus Grosshadern, Marchioninistrasse 15, Munich. SekrMED3@med.uni-muenchen.de
D014408:Biomarkers, Tumor / Q000235:genetics; D002869:Chromosome Aberrations; D004252:DNA Mutational Analysis; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D007938:Leukemia / Q000175:diagnosis / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000473:pathology* / Q000628:therapy; D011379:Prognosis
D014408:Biomarkers, Tumor